Dr. Ludger Dinkelborg is a distinguished leader in radiopharmaceutical development with over 25 years of experience in the pharmaceutical industry. He earned his PhD in organic chemistry from the University of Münster, Germany, and began his career at Schering AG (now part of Bayer), where he advanced from research chemist to head of radiopharmacy projects. During his tenure at Bayer Schering Pharma, Dr. Dinkelborg spearheaded the discovery and clinical development of several innovative imaging agents, including the prostate cancer tracer 18F-DCFPyL (Pylarify), which received FDA approval and has become a cornerstone in precision oncology diagnostics. In 2012, Dr. Dinkelborg joined Piramal Imaging GmbH as Managing Director, where he expanded the company's radiotracer portfolio and forged key partnerships for global commercialization. His strategic vision led to the successful launch of multiple PET imaging agents targeting neurodegenerative diseases and oncology, earning him recognition as a pioneer in molecular imaging. Under his leadership, Piramal advanced several candidates into late-stage clinical trials, solidifying its position in the competitive radiopharmaceutical market. As Head of Research and Development at Lantheus Holdings, Inc. since 2021, Dr. Dinkelborg oversees a robust pipeline of next-generation radiopharmaceuticals, focusing on theranostics and targeted therapies for cancer and cardiovascular diseases. He drives innovation in radioligand therapies and novel tracers, leveraging Lantheus' manufacturing expertise to accelerate from discovery to market. His efforts have positioned the company at the forefront of nuclear medicine, with several programs advancing toward regulatory milestones, reflecting his commitment to transforming patient outcomes through cutting-edge science.